Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of lisdexamfetamine dimesylate capsules in children and adolescents with ADHD
CTR20250155Phase 3Active
- Sponsor
- Sichuan Kered Pharmaceutical
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lisdexamfetamine in attention deficit hyperactivity disorder (ADHD), sponsored by Sichuan Kered Pharmaceutical. Primary endpoint: Change from baseline in ADHD-RS-IV-Parent total score. Started Jun 2025; status: active.
02
Drugs
lisdexamfetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on CTR20250155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250155.